Samsung Epis Expands Global R&D: New Beijing Hub Accelerates ADC Oncology InnovationSamsung Epis Holdings opens its first overseas R&D hub in Beijing, focusing on antibody‑drug conjugates and boosting global biopharma innovation.SAMSUNG EPISHOLDINGS CO LTD Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 01/07/2026, 15:47 3 minutes to read